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Abstract
In 30–50% of patients with fever of unknown origin (IUO) no explanation for the fever can be found. Prognosis and effects of empirical
treatment of these patients are largely unknown.
With this retrospective, questionnaire based corort study in all unexplained FUO patients in an expert center between 2003 and
2014 we studied mortality and outcome.
In 131 of 274 FUO patients, FUO remained unexplained. Ninety-nine of them responded to the long-term follow up questionnaire.
Adter a median duration of follow-up of 60 months, spontaneous remission of fever occured in 47.3%. Empirical treatment was
effective in 66.7% of patients. Mortality was 6.9%. The cause of death was considered not to be related to the febrile disease in ﬁve
out of six patients. Ten out of 99 responders reported to have received a ﬁnal explanation for FUO after evaluation in the expertise
center, but this diagnosis could not be conﬁrmed in six cases and was considered to be an unlikely explanation for FUO in four out of
six cases.
We conclude that mortality in unexplained FUO is low en mostly unrelated to the febrile disease. Spontaneous resolution of fever is
common. Empirical treatment prescribed by an expert physician is often effective, but should be avoided untill all diagnostic
possibilities have been exhaused.
Abbreviations: FUO = fever of unknown origin, IUO = inﬂammation of unknown origin.
Keywords: fever of unknown origin, mortality, prognosis, survival, therapy, treatment
1. Introduction
Fever of unknown origin (FUO) and inﬂammation of unknown
origin (IUO) are complex diagnostic problems encountered by
many different medical specialists. FUO/IUO is deﬁned as at least
3 weeks duration of fever or elevated inﬂammatory markers in an
immunocompetent patient, for which no cause is found despite
an extensive workup.[1–4] (Table 1).
In recent Dutch and other western-European cohorts,[1,5–9]
30% to 50% of patients remain undiagnosed despite extensive
evaluation. The prognosis of these patients is not well known. The
onlywestern-European study speciﬁcallydesigned todetermine the
prognosis of FUO patients reported a mortality of 2.4% in 168
undiagnosed patients. In that study, all deaths in patients with
unexplained FUO occurred during the index admission.[10]
Although spontaneous resolution of FUO was reported in
43% to 75% of undiagnosed cases[1,3,6,11], many patients with
undiagnosed FUO are empirically treated with antibiotics,
corticosteroids, or other anti-inﬂammatory drugs. The effects
of these treatments are largely unknown.
We performed a questionnaire-based long-term follow-up study
on treatment and prognosis in patients with FUO that remained
undiagnosed during the 2 most recent Dutch FUO studies.[1,9]
2. Materials and methods
2.1. Patient selection
All patients that remained undiagnosed in the 2 most recent
Dutch FUO studies were eligible for inclusion. Both studies were
performed in the Radboud university medical center, a 630-bed
tertiary referral center and expertise center for FUO. These 2
studies included 245 patients with FUO and 64 patients with
IUO. Inclusion criteria are described in detail elsewhere.[1,9]
2.2. Medical ethics approval
This study was assessed by the medical ethics committee Arnhem-
Nijmegen (registration number 2014/309) and according to
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Dutch law it was exempt from approval and the collection of
written informed consent because of its non-invasive design and
anonymous storage of patient data.
2.3. Data collection
2.3.1. Medical records. Demographic data and data on FUO,
including age of onset, date of ﬁrst presentation, fever pattern,
treatment, outcome, and survival were collected from the medical
records.
2.3.2. Surveys. Eligible patients were contacted by phone. A
standardized interview (English translation in Supplement 1,
http://links.lww.com/MD/C308) was performed. If calls
remained unanswered, a standardized questionnaire including
the same questions as the telephonic interview was sent out either
by regular mail or email. A prepaid pre-addressed return envelope
was included in all surveys sent out by regular mail. E-mails
contained a hyperlink to a secured online survey. Patients that did
not complete the survey within 2 weeks were sent a reminder.
Online survey responses were only included in the analyses if they
were fully completed.
If patients reported to have visited another hospital because of
FUO or IUO after the end of the FUO study, they were asked
permission to approach the health-care provider to collect
relevant medical data. If patients gave consent, they were sent a
paper informed consent form and prepaid pre-addressed return
envelope. These forms were used to collect relevant medical data
from other hospitals. The proof of the diagnosis and the
likelihood of being related to FUO were discussed between all
investigators for all ﬁnal diagnoses until consensus was reached.
Diagnoses were categorized as conﬁrmed when considered
sufﬁciently validated based on the collected data. If insufﬁciently
proven, diagnoses were categorized as unconﬁrmed.
Patients had not been instructed to regularly measure their
body temperature, but did so on their own initiative. Continuous
fever or inﬂammation was considered cured if patients had been
fever or symptom free for at least 1 week at the time of the
questionnaire. Recurrent fever or inﬂammation was considered
cured based on the individual fever or inﬂammation pattern. If
any information on remission of fever or inﬂammation was
unclear, it was discussed between the investigators until
consensus was reached.
For patients responding to the questionnaire, duration of
follow upwas deﬁned as the time between the ﬁrst presentation to
the Radboudumc and the date on which the questionnaire was
completed. For non-responders, duration of follow up was
deﬁned as the interval between the ﬁrst presentation and the last
contact with the Radboudumc during the FUO study.
2.4. Statistical analysis
Categorical data are represented as number (percentage) and
compared by Fisher exact test. Continuous data are represented
as median (range) and compared using two-tailed Mann–
Whitney U test. A P-value of <.05 was considered statistically
signiﬁcant. Statistical analyses were performed using SPSS for
Windows, version 22.0 (IBM, Armonk, New York).
3. Results
3.1. Patient characteristics
The 2 most recent Dutch cohort studies on FUO/IUO included a
total of 274 patients, in 131 (47.8%) of which the cause for the
fever or inﬂammation remained unknown. Sixty-three patients
with unexplained FUO (48.1%)weremen. Total median duration
of follow up was 60 months (range, 0–177 months). (Table 2).
3.2. Prognosis during FUO study
3.2.1. Treatment during FUO study. Median duration of
follow-up during both FUO studies was 18 months (range, 0–
58 months). Fifty-three of the 131 patients with unexplained
FUO (40.5%) were treated during the FUO studies. Steroids and
drugs in the category other drugs were the most commonly used
(N=26, 19.8%) (Table 3).
Of all 53 patients that received at least 1 treatment for
unexplained FUO during the FUO study, 11 (20.6%) did not
respond to the questionnaire. Remission of fever upon treatment
was noted in the medical chart in 4 of them (36.6%).
Of the 71 patients that remained untreated during the FUO
study, 11 (15.4%) did not respond to the questionnaire. In 7 of
these patients (63.6%) spontaneous remission of fever was noted
in the medical charts. Median duration of fever in these patients
was 3.5 months (range 0–38 months).
3.2.2. Survival. Three patients (2.3%) died during the FUO
studies. The cause of death remained unknown in 1. The 2 other
patients died of heart failure, which was regarded unrelated to the
Table 1
Deﬁnition of fever of unknown origin (FUO) and inﬂammation of unknown origin (IUO)[1–4].
1. On several separate occasions:
- Fever ≥38.3 °C (≥101 °F) (for FUO) OR
- Elevated erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or serum amyloid A (SAA) with body temperature <38.3 °C (<101 °F) (for IUO)
2. Duration of illness at least 3 weeks
3. No diagnosis despite extensive evaluation including (but not limited to):
Extensive medical history and physical examination
Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) or serum amyloid A (SAA), hemoglobin, platelet count, leukocyte count including differentiation, sodium,
potassium, calcium, creatinin, total serum protein en protein electrophoresis, alkaline phosphatase (AF), aspartate aminotranspherase (ASAT), alanine aminotranspherase
(ALAT), lactate dehydrogenase (LDH), creatinin kinase (CK), antinuclear antibodies (ANA), rheumatoid factor (RF), microscopic urinalysis, ferritin
Blood cultures (minimal 3), urine culture, tuberculin skin test or interferon gamma release assay
Chest x-ray, abdominal ultrasound, or chest and abdominal CT scan
4. No known immunocompromised state, excluding the following:
Neutropenia (leukocyte count <1.0109/L or granulocyte count <0.5109/L) during at least 1 week within the 3 months before the start of the fever
Known human immunodeﬁciency virus (HIV) infection
Known hypogammaglobulinemia (IgG <50% of normal value)
Use of 10mg prednisone or equivalent dose of corticosteroids during at least 2 weeks in the 3 months before the start of the fever
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underlying cause of the fever, after 38 and 42 months from
presentation, respectively. (Table 4).
3.3. Prognosis during long-term follow-up
Ninety-nine of the 131 patients with unexplained FUO (75.6%)
responded to the questionnaire for long-term follow-up. Median
duration of follow-up in these patients was 75 months (range 28–
177 months). (Table 2)
3.3.1. Treatment during long-term follow-up. Fifty-three of
the 64 patients that received some form of treatment for
unexplained FUO during the FUO study (82.8%) responded to
the questionnaire. Twenty-eight of them (52.8%) reported that
their fever had resolved. Median duration from the start of the
fever to remission was 21 months (range 0–86 months).
Forty-six patients who remained untreated during the FUO
study responded to the questionnaire and 20 of them (43.5%)
reported spontaneous remission of fever. In untreated patients,
median duration of fever was 2.0 months (range 0–45 months).
This was not signiﬁcantly different from treated patients
(P= .19).
Ten of the 99 responders (10.1%) reported to have received
some form of treatment for unexplained FUO that was not
reported during the FUO studies (Table 3). In only 3 of them
treatment was deﬁnitely started after the FUO study. One of these
3 reported to have been prescribed anakinra, the second used
omalizumab and the third one reported to have been treated
with nadroparine and acenocoumarol, all 3 in absence of an
explanation.
Of all empirical treatments, 66.7%had been effective (Table 3).
3.3.2. Survival during long-term follow-up. Six patients
(6.1%) died during long-term follow-up (Table 4). Median
duration from ﬁrst presentation to death was 13 months (range
3–24 months) and median age at death was 73 years (range 64–
79 years). The cause of death was known in 4 patients and was
considered unrelated to FUO in 3 of them. In 1 patient, who died
from breast cancer, it was unclear whether the tumor could have
been responsible for the febrile illness (Table 4).
3.3.3. Further investigation during long-term follow-up.
Twenty-six of 99 responders (26.3%) reported to have visited
another health-care provider because of FUO after the FUO
study. These patients had visited a median of one health-care
provider (range 1–3 providers).
Table 2
Patient characteristics of 131 patients that remained undiagnosed during previous Dutch fever of unknown origin studies.
All patients N=131 Responders N=99 Non-responders N=32 P-value
∗
Gender Male 63 (48.1%) 46 (46.5%) 17 (53.1%) .55
Fever pattern Continuous 32 (24.4%) 23 (23.2%) 9 (28.1%) .64
Episodical 99 (75.6%) 76 (76.8%) 23 (71.9%)
Median age at start fever (range) 44 (0–87) 44 (0–81) 43 (0–87) .50
Median age at ﬁrst study contact (range) 45 (18–87) 45 (18–81) 47 (19–87) .80
Duration of FUO/IUO at ﬁrst presentation (months, [range]) 12 (0–579) 17 (0–579) 6.5 (0–337) .016
Median duration of follow up in FUO study (months, [range]) 20 (0–169) 20 (0–169) 18 (0–58) .42
Median duration of total follow up (months, [range]) 60 (0–177†) 75 (28–177) 18 (0–58) <.001
Study type Telephone 84 (64.1%) 84 (84.8%) N/A N/A
Online 10 (7.6%) 10 (10.1%) N/A N/A
Post 5 (3.8%) 5 (5.1%) N/A N/A
No current contact
information available
2 (1.5%) N/A 2 (6.3%) N/A
Participant Patient 93 (71.0%) 93 (93.9%) N/A N/A
Family member 6 (4.6%) 6 (6.1%) N/A N/A
FUO= fever of unknown origin, IUO= inﬂammation of unknown origin, N/A=not applicable.
∗
Responders versus non responders.
† One patient exceeded the maximum duration of follow up of 157 months (from 2003 to 2016). This patient presented with FUO in 2001 and was included in the FUO study in 2003 when PET/CT was made
because of still unexplained FUO.
Table 3
Treatment and efﬁcacy of treatment in patients with unexplained
FUO
∗
.
Treatment
Number of
patients during
FUO study (%)
N=131
Number of
patients after
FUO study (%)
N=99
Effectiveness
(%)†
Antibiotics 14 (10.7%) 3 (3.0%)‡ 12 (70.6%)
NSAIDs/acetaminophen 17 (13.0%) 3 (3.0%)‡ 13 (65.0%)
Corticosteroids 26 (19.8%) 22 (84.6%)
Immunosuppressive drugs 6 (4.6%) 4 (66.7%)
Etanercept 1 (0.8%)
Inﬂiximab 1 (0.8%)
Methotrexate 3 (2.3%)
Tocilizumab 1 (0.8%)
Anakinra 20 (15.3%) 1 (1.0%) 14 (66.7%)
Chemotherapy 2 (1.5%) 0
Other drugs 26 (19.8%) 2 (2.0%) 15 (53.6%)
Colchicine
15 (11.5%)
Other treatment 3 (2.3%) 4 (100%)
Psychotherapy 2 (1.5%)
Oral anticonceptives 1 (0.8%) 1 (1.1%)‡
Acupuncture
Median 66.7%
FUO= fever of unknown origin, NSAIDs=non-steroidal anti-inﬂammatory drugs.
∗
Patients could have used several kinds of drug during follow up.
† Effectiveness was deﬁned as at least temporarily effect on fever/inﬂammation and complaints.
‡ These patients reported this treatment for FUO in the questionnaire. As starting dates were unknown
and these treatments were not registered during the FUO study, it was unclear whether this treatment
was initiated before or after the FUO study.
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Ten patients (10.1%) reported that a ﬁnal diagnosis had been
made after the FUO study (Table 5). Median duration from the
ﬁrst visit to the Radboudumc to the ﬁnal diagnosis was 3 years
(range 0.6–11 years). In 6 of the 10 patients that reported a
diagnosis after the FUO study (60.0%), the diagnosis could not
be conﬁrmed after further investigation. Of all 6 unconﬁrmed
diagnoses, 4 (66.7%) were considered unlikely to be related to
FUO, 1 (16.7%) was considered possibly related to FUO, and 1
(16.7%) was considered a likely explanation for the FUO
(Table 5).
4. Discussion
Of the 131 patients with FUO that remained unexplained in the 2
most recent Dutch FUO studies,[1,9] 9 died during a median
follow up of 5 years. In untreated patients, spontaneous
remission of fever was present in 47.3%.
Little is known on the prognosis of patients with unexplained
FUO/IUO. Only a single study speciﬁcally designed to address
prognosis in FUO has been performed until now.[10] In this study
4 of 168 patients with unexplained FUO died during a follow up
of at least 6 months, and in only 2 cases no diagnosis could be
made upon autopsy. A previous and smaller Dutch FUO study
has shown mortality rates of 4.0%.[11] Other western-European
studies showed mortality rates between 2.0% and 19.0% in
unexplained FUO.[3,5–8] The differences between these studies
may arise from differences in patient selection, study design, and
differences in health care systems. With a median follow up of 60
months, our study has the longest duration of follow up of all
recent FUO studies.
In the 6 patients that died with a known cause of death, death
was considered unrelated to the febrile disease in 5. All of these
patients died from a frequently seen cardiac disease. In the sixth
patient it remains unknown whether the breast cancer she died
from could have been present at the time of FUO.
Spontaneous remission of FUO/IUO occurred in 47.3% of
untreated patients. In other western-European studies this
percentages varies between 15% and 88%,[3,5–7,11–13] and in
non-western European studies between 15% and 100%.[14–19]
The wide range of duration of fever shows that it may take a long
time until fever resolves.
Empirical treatment was effective in 66.7% of patients, with a
median duration of fever of 21 months. Based on the wide range
of duration of fever, it could be debated whether the empirical
treatment was truly effective, as it cannot be proven that the fever
would have resolved spontaneously.
In 2 of the 3 patients reporting to have been treated for FUO
after the FUO study, treatment with either anakinra or
omalizumab was considered related to FUO, but was question-
able in the third one, reporting having used acenocoumarol and
nadroparine in absence of a diagnosis. Of these 3 patients, only in
the patient that was started on omalimumab the reason for the
start of this therapy was known: chronic urticaria in absence of a
deﬁnite diagnosis.
It could be debated whether the empirical therapy initiated for
unexplained FUO in the 2 recent Dutch FUO studies could have
inﬂuenced the diagnostic yield in these studies. Of the 99
responders in this study, 26.3% reported to have visited another
health care provider because of FUO after no explanation for
FUO had been found in our FUO expertise center. This illustrates
that the vast majority of patients with FUO/IUO is sufﬁciently
reassured when no diagnosis can be found in an FUO expertise
center. Ten out of the 99 patients in our study reported to have
received a ﬁnal diagnosis for their FUO/IUO after the FUO study,
but this diagnosis was considered not to be related to the FUO in
half of them. Diagnoses with possible relation to FUO were
recurrent aspiration, drug fever, Streptococcus viridians bacter-
aemia, thyroiditis, and familial Mediterranean fever. The
diagnoses recurrent aspiration and S viridians bacteraemia
may have been masked by the use of antibiotics, but 1 of these
2 patients had not been treated with antibiotics during the FUO
study. Of all 5 patients with an unlikely diagnosis, 1 patient had
been diagnosed with Hodgkin lymphoma, and this patient had
been treated with corticosteroids during the FUO study.
However, the PET/CT that showed no signs of lymphoma
during the FUO study, and the interval between presentation and
Table 4
Characteristics of undiagnosed patients with fever of unknown origin that died.
Gender,
age at
presentation
Duration from
presentation to
death (mo) Cause of death (source)
Fever at time
of death
Death related
to FUO
1 M, 81
∗
38 Congestive heart failure due to previous and recent
myocardial infarction with pre-existing valvular
heart disease, pulmonary hypertension and pulmonary
embolism. No signs of endocarditis. (Autopsy report)
No, remission on therapy No
2 M, 78
∗
42 Congestive heart failure upon rehydration therapy.
Dehydration upon refusal of oral intake due
to oral pemphigus vulgaris (medical record)
No, spontaneous remission No
3 M, 81
∗,† ? Unknown (nonresponder) Unknown Unknown
4 M, 69 6 Congestive heart failure associated with pneumonia
and Lewy body dementia (medical record)
Yes, no therapy No
5 M, 63 13 Unknown heart disease (family member) Yes, despite therapy No
6 M, 77 3 Cardiac arrest (family member) Yes, despite therapy No
7 F, 77† 24 Breast cancer (family member) Unknown Unknown
8 M, 72† 16 Unknown (nonresponder) Unknown Unknown
9 M, 87† ? Unknown (nonresponder) Unknown Unknown
F= Female, M=Male, FUO= fever of unknown origin.
∗
This patient died during the FUO study.
† This patient had been included in the FUO study by Bleeker-Rovers et al[1] from a community hospital and further data were unavailable.
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diagnosis of 3.5 years make a relationwith FUOunlikely and it is,
therefore, implausible that this diagnosis was missed during the
FUO study.
Although the data from this study illustrate effectiveness of for
instance corticosteroids in patients with FUO/IUO, empirical
treatment should be used with extreme caution in FUO/IUO
patients. Making a ﬁnal diagnosis is of foremost importance and
should have priority above empirical treatment, as making a ﬁnal
diagnosis may lead to different life-saving treatment choices. A
classical example of this is lymphoma, in which corticosteroids
may lead to remission of fever and may also reduce tumor mass,
but without full cure. Steroids may mask important diagnostic
clues, decreasing the chance of making a ﬁnal diagnosis and
initiation of life-saving therapy. Besides that, corticosteroids and
other immunosuppressive drugs frequently have serious infec-
tious andmetabolic side effects. Because of this, empirical therapy
should be postponed until all diagnostic possibilities have become
exhausted and clinical deterioration is present. In the current
study, all therapeutic choices were based on expert opinion,
usually after discussion among the FUO experts in our center.
What type of drug to use for empirical treatment largely depends
on the clinical picture, the experience of the treating physician,
and the presence or absence of a strongly suspected but
impossible to prove diagnosis. In the current study 20% of
patients were treated with corticosteroids. This is similar to other
western-European FUO studies, were 8.1% to 40.9% of
undiagnosed patients received these drugs.[6,8,20] Fifteen percent
of patients in the current studywere treatedwith the interleukin-1
receptor antagonist anakinra. This drug is effective in auto-
inﬂammatory diseases. An increasing number of these are
described in literature, but a signiﬁcant proportion of patients
with clear symptoms of autoinﬂammation cannot be diagnosed
with one of the known autoinﬂammatory diseases, as these
diseases are extremely rare and there are no investigations,
besides genetic mutation analysis in some autoinﬂammatory
diseases, that can deﬁnitely prove the presence of autoinﬂamma-
tion. After exclusion of other causes, anakinra could be tried in
patients with symptoms of autoinﬂammation, such as fever, skin
rash, and/or serositis.[21] In most autoinﬂammatory diseases,
anakinra has a rapid and substantial effect on fever and other
symptoms. A rapid positive reaction to anakinra almost certainly
proves the presence of autoinﬂammation, which is caused by
overproduction of interleukin-1. The effectiveness of 66.7%
found in this study illustrates that experts on this type of diseases
are able to distinguish autoinﬂammation from other causes of
FUO.
The main limitation of this study is its retrospective
questionnaire-based design, which may induce selection and
recall bias. To overcome this limitation, we compared the results
from the questionnaires to results from medical charts. The
study’s long duration of follow-up did not induce a signiﬁcant
loss to follow-up, as 75% of all undiagnosed FUO patients seen
between 2003 and 2014 responded to the questionnaire.
Furthermore, in patients that did not respond to the long-term
follow-up questionnaire, data from available medical charts were
used to complete missing data.
In conclusion, during a median follow up of 60 months,
mortality in undiagnosed FUO/IUO patients was low and mostly
unrelated to the febrile disease. Spontaneous resolution of fever
occurs in approximately half of undiagnosed patients, but may
take a long time to become apparent. Empirical treatment can be
effective, but should be postponed in favor of making a ﬁnal
diagnosis, which may inﬂuence prognosis.T
a
b
le
5
(c
o
nt
in
ue
d
).
Ge
nd
er
,
ag
e∗
(y
)
Fe
ve
r
pa
tte
rn
Di
ag
no
si
s†
Di
ag
no
st
ic
ca
te
go
ry
Tr
ea
tm
en
t
He
at
h
ca
re
pr
ov
id
er
Du
ra
tio
n
un
til
di
ag
no
si
s
(m
o)
‡
Op
in
io
n
on
lik
el
ih
oo
d
of
re
la
tio
n
to
FU
Ox
m
ar
ro
w
as
pi
ra
te
be
fo
re
re
fe
rra
lh
ad
be
en
no
rm
al
.
No
lym
ph
no
de
bi
op
sy
ha
d
be
en
do
ne
.
9
F,
68
Re
cu
rre
nt
Q-
fe
ve
r
(u
nc
on
ﬁ
rm
ed
)
In
fe
ct
io
n
No
ne
Co
m
m
un
ity
ho
sp
ita
l
24
Re
la
tio
ns
hi
p
un
lik
el
y.
Q-
fe
ve
r
se
ro
lo
gy
Ig
M
an
d
Ig
G
ha
d
be
en
no
rm
al
du
rin
g
FU
O
ev
al
ua
tio
n.
W
e
di
d
no
t
re
ce
ive
an
y
da
ta
fro
m
th
e
co
ns
ul
ta
nt
w
ho
di
ag
no
se
d
th
is
pa
tie
nt
.
10
F,
63
Re
cu
rre
nt
Dr
ug
fe
ve
r
on
ac
et
am
in
op
he
n
or
NS
AI
Ds
(u
nc
on
ﬁ
rm
ed
)
M
is
ce
lla
ne
ou
s
St
op a
ce
ta
m
in
op
he
n
an
d
NS
AI
Ds
Se
lf
di
ag
no
si
s
49
Re
la
tio
ns
hi
p
un
lik
el
y.
Th
e
pa
tie
nt
re
po
rte
d
th
at
sh
e
be
ca
m
e
fe
br
ile
m
in
ut
es
af
te
r
in
ge
st
io
n
of
NS
AI
Ds
/a
ce
ta
m
in
op
he
n
an
d
be
ca
m
e
fe
ve
r
fre
e
af
te
r
ce
ss
at
io
n
of
th
es
e
dr
ug
s.
Pa
th
op
hy
si
ol
og
ic
al
ly
th
e
re
la
tio
n
is
ve
ry
un
lik
el
y,
bu
t
fe
ve
r
is
a
re
po
rte
d
ra
re
si
de
ef
fe
ct
of
ac
et
am
in
op
he
n
(0
.1
–
1%
of
ca
se
s)
F=
Fe
m
al
e,
FM
F=
Fa
m
ilia
lM
ed
ite
rra
ne
an
fe
ve
r,
FU
O
=
fe
ve
r
of
un
kn
ow
n
or
ig
in
,
M
=
m
al
e,
NI
ID
=
no
n-
in
fe
ct
io
us
in
ﬂ
am
m
at
or
y
di
se
as
e,
NS
AI
Ds
=
no
n-
st
er
oi
da
la
nt
i-i
nﬂ
am
m
at
or
y
dr
ug
s.
∗
Ag
e
at
ﬁ
rs
t
pr
es
en
ta
tio
n
at
Ra
db
ou
du
m
c.
†
Di
ag
no
si
s
w
as
co
nﬁ
rm
ed
if
co
rre
sp
on
de
nc
e
fro
m
th
e
he
al
th
ca
re
pr
ov
id
er
w
ho
m
ad
e
th
e
di
ag
no
si
s
sh
ow
ed
de
ﬁ
ni
te
pr
oo
f.
Di
ag
no
si
s
w
as
co
ns
id
er
ed
un
co
nﬁ
rm
ed
if
co
rre
sp
on
de
nc
e
di
d
no
ts
ho
w
de
ﬁ
ni
te
pr
oo
fo
rn
o
co
rre
sp
on
de
nc
e
w
as
re
ce
ive
d
fro
m
th
e
di
ag
no
si
ng
he
al
th
ca
re
pr
ov
id
er
.
‡
Fr
om
th
e
ﬁ
rs
t
pr
es
en
ta
tio
n
at
Ra
db
ou
du
m
c
to
di
ag
no
si
s.
x S
ub
je
ct
ive
op
in
io
n
of
th
e
st
ud
y
te
am
on
th
e
lik
el
in
es
s
th
at
th
e
di
ag
no
si
s
w
as
re
la
te
d
to
th
e
ep
is
od
e(
s)
of
FU
O.
Mulders-Manders et al. Medicine (2018) 97:25 Medicine
6
Author contributions
CM designed the study, collected data, analyzed the data, and
drafted ﬁrst and following version of manuscript. CE collected
data. AS, JWMM, and CPB designed the study, supported data
collection, and treated the patients. All authors approved the ﬁnal
version of the manuscript.
Conceptualization: Catharina M. Mulders-Manders, Anna
Simon, and Chantal P. Bleeker-Rovers.
Data curation: Celeste Engwerda and Catharina M. Mulders-
Manders.
Formal analysis: Catharina M. Mulders-Manders.
Methodology: Anna Simon, Jos W.M. van der Meer, Chantal P.
Bleeker-Rovers.
Resources: Chantal P. Bleeker-Rovers, Anna Simon and Jos WM
van der Meer.
Supervision: Chantal P. Bleeker-Rovers and Anna Simon.
Writing – original draft:CatharinaM.Mulders-Manders, Celeste
Engwerda.
Writing – review and editing: Catharina M. Mulders-Manders,
Anna Simon, Jos W.M. van der Meer, Chantal P. Bleeker-
Rovers.
References
[1] Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter
study on fever of unknown origin: the yield of a structured diagnostic
protocol. Medicine (Baltimore) 2007;86:26–38.
[2] Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown
origin. Clin Med 2015;15:280–4.
[3] Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown
origin in adults: 40 years on. J Intern Med 2003;253:263–75.
[4] Bleeker-Rovers C, Meer JWMvd. Fever of unknown origin. Harisson’s
Principles of Internal Medicine. 19 ed. New York: McGraw-Hill
Education; 2015.
[5] Pedersen TI, Roed C, Knudsen LS, et al. Fever of unknown origin: a
retrospective study of 52 cases with evaluation of the diagnostic utility of
FDG-PET/CT. Scand J Infect Dis 2012;44:18–23.
[6] Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a
non-university hospital. Scand J Infect Dis 2006;38:632–8.
[7] Robine A, Hot A, Maucort-Boulch D, et al. Fever of unknown origin
in the 2000s: evaluation of 103 cases over eleven years. Presse Med
2014;43:e233–40.
[8] Vanderschueren S, Del Biondo E, Ruttens D, et al. Inﬂammation of
unknown origin versus fever of unknown origin: two of a kind. Eur J
Intern Med 2009;20:415–8.
[9] Mulders-Manders C, Pietersz G, Simon A, et al. Referral of patients with
fever of unknown origin to an expertise center has high diagnostic and
therapeutic value. QJM 2014;110:793–801.
[10] Vanderschueren S, Eyckmans T, De Munter P, et al. Mortality in
patients presenting with fever of unknown origin. Acta Clin Belg
2014;69:12–6.
[11] de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown
origin (FUO). I A. prospective multicenter study of 167 patients with
FUO, using ﬁxed epidemiologic entry criteria. The Netherlands FUO
Study Group. Medicine (Baltimore) 1997;76:392–400.
[12] Knockaert DC, Vanneste LJ, Bobbaers HJ. Recurrent or episodic fever of
unknown origin. Review of 45 cases and survey of the literature.
Medicine (Baltimore) 1993;72:184–96.
[13] de Kleijn EM, van der Meer JW. Fever of unknown origin (FUO): report
on 53 patients in a Dutch university hospital. Neth J Med 1995;47:
54–60.
[14] Saltoglu N, Tasova Y, Midikli D, et al. Fever of unknown origin in
Turkey: evaluation of 87 cases during a nine-year-period of study. J Infect
2004;48:81–5.
[15] Ali-Eldin FA, Abdelhakam SM, Ali-Eldin ZA. Clinical spectrum of fever
of unknown origin among adult Egyptian patients admitted to Ain Shams
University Hospitals: a hospital based study. J Egypt Soc Parasitol
2011;41:379–86.
[16] Tabak F, Mert A, Celik AD, et al. Fever of unknown origin in Turkey.
Infection 2003;31:417–20.
[17] Moawad MA, Bassil H, Elsherif M, et al. Fever of unknown origin: 98
cases from Saudi Arabia. Ann Saudi Med 2010;30:289–94.
[18] Ryuko H, Otsuka F. A comprehensive analysis of 174 febrile patients
admitted to Okayama University Hospital. Acta Med Okayama 2013;
67:227–37.
[19] Mir T, Nabi Dhobi G, Nabi Koul A, et al. Clinical proﬁle of
classical Fever of unknown origin (FUO). Caspian J Intern Med 2014;
5:35–9.
[20] Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged
febrile illness to fever of unknown origin: the challenge continues. Arch
Intern Med 2003;163:1033–41.
[21] Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic
challenge and treatment option for systemic autoinﬂammatory disorders
of undeﬁned etiology. JCI Insight 2016;1:e86336.
Mulders-Manders et al. Medicine (2018) 97:25 www.md-journal.com
7
